MARKET

ZYME

ZYME

Zymeworks
NASDAQ
23.89
-2.71
-10.19%
After Hours: 24.02 +0.13 +0.52% 18:35 05/08 EDT
OPEN
26.21
PREV CLOSE
26.60
HIGH
26.21
LOW
23.39
VOLUME
1.45M
TURNOVER
--
52 WEEK HIGH
29.75
52 WEEK LOW
10.86
MARKET CAP
1.76B
P/E (TTM)
-22.2047
1D
5D
1M
3M
1Y
5Y
1D
Zymeworks’ Earnings Call Balances Progress And Pressure
TipRanks · 1d ago
Zymeworks (ZYME) Q4 Loss And TTM US$81 Million Deficit Test Bullish Profitability Narrative
Simply Wall St · 1d ago
Zymeworks Down Over 9%, on Pace for Largest Percent Decrease Since December 2022 -- Data Talk
Dow Jones · 1d ago
Zymeworks Is Maintained at Overweight by Wells Fargo
Dow Jones · 1d ago
Zymeworks Price Target Raised to $34.00/Share From $33.00 by Wells Fargo
Dow Jones · 1d ago
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $34
Benzinga · 1d ago
Zymeworks (ZYME) Gets a Buy from Wells Fargo
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Thermo Fisher (TMO) and Claritev (CTEV)
TipRanks · 1d ago
More
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Webull offers Zymeworks Inc stock information, including NASDAQ: ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.